skip to Main Content

NICE Recommends Celgene’s Pancreatic Cancer Treatment Abraxane for NHS Use

Newsfeed image, light gray text on dark gray background
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Celgene’s nab-paclitaxel as a life-extending treatment for patients with progressive pancreatic cancer.
Also known as abraxane, nab-paclitaxel will be routinely available for eligible patients on the National Health Service (NHS) England. Read more . . .

Back To Top